Specificities mediating neutralization breadth and potency in the top 42 Protocol C neutralizers.

<p>(A) Samples are ranked by their neutralization score on the 37-virus panel (37vP) (S4 Fig in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005369#ppat.1005369.s001" target="_blank">S1 Text</a> and S2 Table in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005369#ppat.1005369.s001" target="_blank">S1 Text</a>). VC: Visit Code (months post infection). Symbols recapitulate the strength of the phenotypes tested using the different approaches detailed in this manuscript (S7-S11 Figures in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1005369#ppat.1005369.s001" target="_blank">S1 Text</a>) to determine the Env epitope region targeted by the plasma broadly neutralizing activity: gp120 absorption of bnAb activity, effect of b6 competition in gp120 absorption experiments, RSC3 binding and neutralization competition, HIV-2 chimera neutralization, viruses produced in presence of kifunensine or bearing mutations. Absent (-), very weak (+/-), weak (+), moderate (++), strong (+++), phenotype was attributed based on i) the median fold or average percent decrease in ID50 and ii) the fraction of viruses which neutralization ID50 was decreased <2 fold, <10 <50 fold or <20%, <40%, <60%, <80%. Blank = not tested, NB: not binding. A dominant specificity was attributed for each sample based on results from all these experiments. UD: Undefined. (B) Overall distribution of dominant nAb specificities mediating plasma neutralization breadth in the top 42 Protocol C neutralizers as detailed in (A).</p>